Arkolith/Insider Trading/AKTS

AKTS Insider Trading

Aktis Oncology, Inc. · full profile →Last filing Jul 8, 2026
Net Selling · 180d
Open-Market Buys (180d)
$0
0 insiders
Open-Market Sells (180d)
$2.8M
2 insiders
Net Insider Flow
-$2.8M
open market, 180d
Reporting Insiders
2
6 P/S transactions
Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

Form 4 insider API

Open-market buys and sells, cluster scans, company flows.

insider.transactions

13F holdings API

Owners, holdings, deltas, point-in-time portfolios.

stock.owners

MCP quickstart

Connect an agent, mint a key, make the first call.

/api/mcp

Recent Form 4 Transactions

100 shown
DateInsiderRoleActionSharesPriceValue
Jul 8, 2026Czibere AkosChief Medical OfficerOption exercise(M)50K—$0
Jul 8, 2026Czibere AkosChief Medical OfficerSell(S)4K$28.71$125K
Jul 8, 2026Czibere AkosChief Medical OfficerSell(S)31K$27.95$862K
Jul 8, 2026Czibere AkosChief Medical OfficerSell(S)15K$27.13$401K
Jul 8, 2026Czibere AkosChief Medical OfficerOption exercise(M)50K$4.95$248K
Jul 8, 2026Ron-Bigger ShulamitChief Operating OfficerOption exercise(M)50K—$0
Jul 8, 2026Ron-Bigger ShulamitChief Operating OfficerSell(S)4K$28.75$121K
Jul 8, 2026Ron-Bigger ShulamitChief Operating OfficerSell(S)30K$27.94$838K
Jul 8, 2026Ron-Bigger ShulamitChief Operating OfficerSell(S)16K$27.13$429K
Jul 8, 2026Ron-Bigger ShulamitChief Operating OfficerOption exercise(M)50K$3.66$183K
Apr 15, 2026Gormley GlennDirectorGrant(A)38K—$0
Jan 12, 2026Nodelman OlegDirectorBuy(P)2.1M$18.00$37.4M
Jan 12, 2026Nodelman OlegDirectorConversion(C)129K——
Jan 12, 2026Nodelman OlegDirectorConversion(C)203K——
Jan 12, 2026Nodelman OlegDirectorConversion(C)2.3M——
Jan 12, 2026Nodelman OlegDirectorBuy(P)144K$18.00$2.6M
Jan 12, 2026Nodelman OlegDirectorConversion(C)9.9M——
Jan 12, 2026Nodelman OlegDirectorConversion(C)997K——
Jan 12, 2026Nodelman OlegDirectorConversion(C)489K——
Jan 12, 2026Nodelman OlegDirectorConversion(C)2.4M——
Jan 12, 2026Nodelman OlegDirectorConversion(C)965K——
Jan 12, 2026Nodelman OlegDirectorConversion(C)86K——
Jan 12, 2026Nodelman OlegDirectorConversion(C)103K——
Jan 12, 2026Kim Helen SusanDirector, 10% OwnerConversion(C)4.9M——
Jan 12, 2026Kim Helen SusanDirector, 10% OwnerBuy(P)23K$18.00$406K
Jan 12, 2026Kim Helen SusanDirector, 10% OwnerConversion(C)135K——
Jan 12, 2026Kim Helen SusanDirector, 10% OwnerBuy(P)812K$18.00$14.6M
Jan 12, 2026Kim Helen SusanDirector, 10% OwnerConversion(C)14.8M—$0
Jan 12, 2026Kim Helen SusanDirector, 10% OwnerConversion(C)101K—$0
Jan 12, 2026Kim Helen SusanDirector, 10% OwnerConversion(C)3.6M—$0
Jan 12, 2026Kim Helen SusanDirector, 10% OwnerConversion(C)412K—$0
Jan 12, 2026Segal Lloyd MitchellDirectorConversion(C)20K——
Jan 12, 2026Segal Lloyd MitchellDirectorConversion(C)25K—$0
Jan 12, 2026Segal Lloyd MitchellDirectorConversion(C)50K—$0
Jan 12, 2026Vida Ventures II-A, LLC10% OwnerConversion(C)4.9M——
Jan 12, 2026Vida Ventures II-A, LLC10% OwnerBuy(P)23K$18.00$406K
Jan 12, 2026Vida Ventures II-A, LLC10% OwnerConversion(C)135K——
Jan 12, 2026Vida Ventures II-A, LLC10% OwnerBuy(P)812K$18.00$14.6M
Jan 12, 2026Vida Ventures II-A, LLC10% OwnerConversion(C)14.8M—$0
Jan 12, 2026Vida Ventures II-A, LLC10% OwnerConversion(C)412K—$0
Jan 12, 2026Vida Ventures II-A, LLC10% OwnerConversion(C)101K—$0
Jan 12, 2026Vida Ventures II-A, LLC10% OwnerConversion(C)3.6M—$0
Jan 12, 2026Gadicke Ansbert10% OwnerConversion(C)1.3M——
Jan 12, 2026Gadicke Ansbert10% OwnerBuy(P)1.1M$18.00$20.0M
Jan 12, 2026Gadicke Ansbert10% OwnerConversion(C)1.6M——
Jan 12, 2026Gadicke Ansbert10% OwnerConversion(C)5.9M——
Jan 12, 2026Gadicke Ansbert10% OwnerConversion(C)6.0M—$0
Jan 12, 2026Gadicke Ansbert10% OwnerConversion(C)5.0M—$0
Jan 12, 2026Gadicke Ansbert10% OwnerConversion(C)22.5M—$0
Jan 12, 2026MPM Oncology Innovations Fund LP10% OwnerConversion(C)1.6M——
Jan 12, 2026MPM Oncology Innovations Fund LP10% OwnerConversion(C)5.9M——
Jan 12, 2026MPM Oncology Innovations Fund LP10% OwnerConversion(C)1.3M——
Jan 12, 2026MPM Oncology Innovations Fund LP10% OwnerBuy(P)1.1M$18.00$20.0M
Jan 12, 2026MPM Oncology Innovations Fund LP10% OwnerConversion(C)22.5M—$0
Jan 12, 2026MPM Oncology Innovations Fund LP10% OwnerConversion(C)6.0M—$0
Jan 12, 2026MPM Oncology Innovations Fund LP10% OwnerConversion(C)5.0M—$0
Jan 12, 2026Foley ToddDirector, 10% OwnerConversion(C)2.7M——
Jan 12, 2026Foley ToddDirector, 10% OwnerBuy(P)233K$18.00$4.2M
Jan 12, 2026Foley ToddDirector, 10% OwnerConversion(C)597K——
Jan 12, 2026Foley ToddDirector, 10% OwnerConversion(C)717K——
Jan 12, 2026Foley ToddDirector, 10% OwnerConversion(C)2.3M—$0
Jan 12, 2026Foley ToddDirector, 10% OwnerConversion(C)2.7M—$0
Jan 12, 2026Foley ToddDirector, 10% OwnerConversion(C)10.2M—$0
Jan 29, 2024Shealy Jeffrey B.Chief Executive Officer, DirectorBuy(P)1.3M$0.50$655K
Jan 29, 2024Boller KennethCFOBuy(P)60K$0.50$30K
Jan 29, 2024Aichele DavidEVP of Business DevelopmentBuy(P)80K$0.50$40K
Jan 29, 2024Geiss ArthurDirectorBuy(P)50K$0.50$25K
Dec 18, 2023Boller KennethCFOSell(S)1K$0.72$864
Dec 18, 2023Aichele DavidEVP of Business DevelopmentSell(S)2K$0.72$1K
Nov 21, 2023Boller KennethCFOSell(S)2K$0.59$1K
Nov 21, 2023Aichele DavidEVP of Business DevelopmentSell(S)3K$0.59$2K
Nov 6, 2023Petock MichelleDirectorGrant(A)185K—$0
Nov 6, 2023Denbaars StevenDirectorGrant(A)38K—$0
Nov 6, 2023Denbaars StevenDirectorGrant(A)77K—$0
Nov 6, 2023McGuire James MichaelDirectorGrant(A)84K—$0
Nov 6, 2023McMahon JeffreyDirectorGrant(A)78K—$0
Nov 6, 2023Rudy Suzanne BDirectorGrant(A)108K—$0
Nov 6, 2023Geiss ArthurDirectorGrant(A)138K—$0
Nov 6, 2023Neal Jerry DDirectorGrant(A)126K—$0
Sep 26, 2023Shealy Jeffrey B.Chief Executive Officer, DirectorGrant(A)80K—$0
Sep 13, 2023Boller KennethCFOGrant(A)40K—$0
Sep 13, 2023Aichele DavidEVP of Business DevelopmentGrant(A)40K—$0
Sep 11, 2023Aichele DavidEVP of Business DevelopmentSell(S)5K$1.09$6K
Sep 11, 2023Boller KennethCFOSell(S)4K$1.10$4K
Aug 18, 2023Denbaars StevenDirectorSell(S)7K$1.83$13K
Mar 23, 2023Petock MichelleDirectorGrant(A)24K—$0
Mar 9, 2023McGuire James MichaelDirectorGrant(A)2K—$0
Feb 10, 2023Boller KennethCFOSell(S)800$4.37$3K
Jan 24, 2023Shealy Jeffrey B.Chief Executive Officer, DirectorGrant(A)327K$2.75$900K
Jan 24, 2023Denbaars StevenDirectorGrant(A)18K$2.75$50K
Dec 20, 2022Shealy Jeffrey B.Chief Executive Officer, DirectorSell(S)2K$2.84$7K
Dec 19, 2022Boller KennethCFOSell(S)1K$2.92$4K
Dec 19, 2022Aichele DavidEVP of Business DevelopmentSell(S)1K$3.14$5K
Dec 6, 2022Denbaars StevenDirectorSell(S)7K$3.57$25K
Nov 28, 2022Shealy Jeffrey B.Chief Executive Officer, DirectorSell(S)2K$3.54$7K
Nov 23, 2022Aichele DavidEVP of Business DevelopmentSell(S)2K$3.52$7K
Nov 23, 2022Boller KennethCFOSell(S)1K$3.52$4K
Nov 21, 2022Shealy Jeffrey B.Chief Executive Officer, DirectorGrant(A)50K—$0
Nov 21, 2022Boller KennethCFOGrant(A)25K—$0
Nov 21, 2022Aichele DavidEVP of Business DevelopmentGrant(A)35K—$0

Data Source

Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.

Coverage: Form 4 filings indexed 2021-04-26 → 2026-07-11. Earlier history is backfilling; this window widens as it deepens.

Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).